Akihiko Koyama, Ph.D., leads the AiM Integrated Biology Engine. His group focuses on generating preclinical data packages, which enable the IND filing of innovative therapeutic compounds for immune-dementia and immuno-oncology.
He has led multiple drug discovery collaboration programs with academic institutes in the United States, the United Kingdom and Japan targeting Alzheimer’s disease and Parkinson’s disease. He serves as a special researcher of the National Institute of Science and Technology policy in Japan.
Akihiko joined Eisai as a molecular biologist in neuroscience at Eisai Tsukuba Research Laboratories in 2003, where he contributed to drug discovery projects targeting Parkinson’s disease. In 2008, he served as a visiting scientist at the laboratory of Dr. Lennart Mucke at the Gladstone Institute of Neurological Disease, during which time he expanded his knowledge of the molecular mechanism of Alzheimer’s disease and Parkinson’s disease utilizing transgenic mice.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)